Young women with HER2-negative breast cancer had improved breast cancer-free interval (BCFI) rates following treatment with ovarian function suppression (OFS) in addition to tamoxifen or exemestane, according to a recent study.
Prostate biopsy using the multiparametric MRI/ultrasound fusion-guided (mpMRI/US) technique improves prostate cancer diagnosis and reduces the detection of clinically insignificant cancers, according to data presented the 15th Urological Association of Asia Congress (UAA 2017) held recently in Hong Kong.
Optimizing perioperative chemotherapy in bladder cancer (BC) presents a clinical challenge, as reflected in a debate at the 15th Urological Association of Asia Congress held in Hong Kong, which focused on the benefits and drawbacks of adjuvant chemotherapy (AC) after radical cystectomy (RC).
Practice-changing results from several clinical trials reported in the past 2 years have offered new effective treatment options for hormone-naïve prostate cancer (PC) patients, according to Dr Gerhardt Attard from the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, who spoke at the 15th Urological Association of Asia Congress (UAA 2017) held recently in Hong Kong.
Chemotherapy has shown dismal results in treatment of metastatic urothelial cancer (UC). The advent of immunotherapy in UC has improved responses and overall survival (OS) in both chemotherapy-pretreated and treatment-naïve patients, according to data presented at the recent 15th Urological Association of Asia Congress held in Hong Kong.
The current protocol for risk stratification of prostate cancer at diagnosis is inaccurate, according to new data from the ProtecT (Prostate Testing for Cancer and Treatment) trial presented at the 15th Urological Association of Asia Congress (UAA 2017) held recently in Hong Kong.
Recent results of a phase II trial showed favourable responses to dasatinib in patients with imatinib-resistant/intolerant or newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP), according to findings presented at the 22nd Congress of European Hematology Association (EHA 2017) held in Madrid, Spain.
Selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres does not improve overall survival (OS) vs sorafenib in patients with locally advanced hepatocellular carcinoma (HCC), although it significantly improves tumour response and reduces adverse events (AEs), the phase III SARAH study has shown.